Pre-clinical evidences of Pyrostegia venusta in the treatment of vitiligo.
暂无分享,去创建一个
M. Otuki | B. Soley | D. Cabrini | P. L. Pawloski | C. G. Moreira | L. Z. B. Carrenho | Priscila Lúcia Pawloski
[1] C. Antoniou,et al. Stimulated human melanocytes express and release interleukin‐8, which is inhibited by luteolin: relevance to early vitiligo , 2014, Clinical and experimental dermatology.
[2] P. Płonka,et al. HGF/SF Increases Number of Skin Melanocytes but Does Not Alter Quality or Quantity of Follicular Melanogenesis , 2013, PloS one.
[3] A. Xu,et al. A mouse model of vitiligo induced by monobenzone , 2013, Experimental dermatology.
[4] M. Mansuri,et al. Vitiligo: interplay between oxidative stress and immune system , 2013, Experimental dermatology.
[5] M. Otuki,et al. Hyperpigmentant activity of leaves and flowers extracts of Pyrostegia venusta on murine B16F10 melanoma. , 2012, Journal of ethnopharmacology.
[6] S. Orlow,et al. Vitiligo inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8 , 2012, The Journal of investigative dermatology.
[7] Poonam Sharma,et al. In vivo antioxidative property, antimicrobial and wound healing activity of flower extracts of Pyrostegia venusta (Ker Gawl) Miers. , 2012, Journal of ethnopharmacology.
[8] Lidiane S. Franqui,et al. Anti-inflammatory and antinociceptive effects of the hydroethanolic extract of the flowers of Pyrostegia venusta in mice , 2012 .
[9] F. Souza-Fonseca-Guimaraes,et al. Effectiveness of Vernonia scorpioides ethanolic extract against skin inflammatory processes. , 2011, Journal of ethnopharmacology.
[10] C. Melief,et al. Monobenzone‐induced depigmentation: from enzymatic blockade to autoimmunity , 2011, Pigment cell & melanoma research.
[11] B. Longley,et al. Topical application of bleaching phenols; in-vivo studies and mechanism of action relevant to melanoma treatment , 2011, Melanoma research.
[12] S. Glassman. Vitiligo, reactive oxygen species and T-cells. , 2011, Clinical science.
[13] Lidiane S. Franqui,et al. Pyrostegia venusta attenuate the sickness behavior induced by lipopolysaccharide in mice. , 2010, Journal of ethnopharmacology.
[14] M. Sprangers,et al. The burden of vitiligo: patient characteristics associated with quality of life. , 2009, Journal of the American Academy of Dermatology.
[15] M. Picardo,et al. Clinical practice. Vitiligo. , 2009, The New England journal of medicine.
[16] Rebat M Halder,et al. Vitiligo update. , 2009, Seminars in cutaneous medicine and surgery.
[17] Wen‐yuan Zhu,et al. The use of botanical extracts as topical skin-lightening agents for the improvement of skin pigmentation disorders. , 2008, The journal of investigative dermatology. Symposium proceedings.
[18] I. Kawase,et al. Glycine inhibits melanogenesis in vitro and causes hypopigmentation in vivo. , 2007, Biological & pharmaceutical bulletin.
[19] Shyamali Roy. Melanin, Melanogenesis, and Vitiligo , 2007 .
[20] U. Kisa,et al. Increased tumor necrosis factor alpha (TNF‐α) and interleukin 1 alpha (IL1‐α) levels in the lesional skin of patients with nonsegmental vitiligo , 2006 .
[21] U. Kisa,et al. Increased tumor necrosis factor alpha (TNF-alpha) and interleukin 1 alpha (IL1-alpha) levels in the lesional skin of patients with nonsegmental vitiligo. , 2006, International journal of dermatology.
[22] M. Ichihashi,et al. Down-regulation of Melanogenesis by Phospholipase D2 through Ubiquitin Proteasome-mediated Degradation of Tyrosinase* , 2004, Journal of Biological Chemistry.
[23] B. Gilchrest,et al. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. , 2004, The Journal of investigative dermatology.
[24] J. Arnhold,et al. Properties, Functions, and Secretion of Human Myeloperoxidase , 2004, Biochemistry (Moscow).
[25] T. Hayashi,et al. Central role of defective apoptosis in autoimmunity. , 2003, Journal of molecular endocrinology.
[26] M. Mockenhaupt,et al. Tumor necrosis factor alpha induces upregulation of CXC-chemokine receptor type II expression and magnifies the proliferative activity of CXC-chemokines in human melanocytes. , 2003, European journal of dermatology : EJD.
[27] S. Moretti,et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. , 2002, Pigment cell research.
[28] J. She,et al. Genetic association of the catalase gene (CAT) with vitiligo susceptibility. , 2002, Pigment cell research.
[29] H. Tagami,et al. Mediators of inflammation involved in UVB erythema. , 2000, Journal of dermatological science.
[30] R. Braz-Filho,et al. Chemical constituents from roots of Pyrostegia venusta and considerations about its medicinal importance , 2000 .
[31] D. Flaherty,et al. Dihydrofluorescein diacetate is superior for detecting intracellular oxidants: comparison with 2',7'-dichlorodihydrofluorescein diacetate, 5(and 6)-carboxy-2',7'-dichlorodihydrofluorescein diacetate, and dihydrorhodamine 123. , 1999, Free radical biology & medicine.
[32] K. Schallreuter. Successful Treatment of Oxidative Stress in Vitiligo , 1999, Skin Pharmacology and Physiology.
[33] O. Damour,et al. Modulation of normal human melanocyte dendricity by growth-promoting agents. , 1993, Pigment cell research.
[34] J. Exton,et al. Activation of phospholipase D by protein kinase C. Evidence for a phosphorylation-independent mechanism. , 1992, Journal of Biological Chemistry.
[35] P. Stanley,et al. Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate. , 1991, Skin pharmacology : the official journal of the Skin Pharmacology Society.
[36] D. Priebat,et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. , 1982, The Journal of investigative dermatology.